X0306 4 2023-02-10 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001734919 Kuhlmann Shirley R. C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 0 1 0 0 EVP and General Counsel Common Stock 2023-02-10 4 A 0 48125 0 A 157620 D Common Stock 2023-02-10 4 A 0 25739 A 183359 D Common Stock 2023-02-10 4 F 0 16291 26.75 D 167068 D Common Stock 2023-02-10 4 F 0 7755 26.75 D 159313 D Common Stock 2023-02-13 4 S 0 21811 26.88 D 137502 D Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 25,739 performance share units granted in the issuer's three prior fiscal years. Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 28, 2022. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6). /s/ Shirley R. Kuhlmann 2023-02-14